# Diaceutics PLC (DXRX.L) fundamentals

Data as of 2026-09-08. LSE, United Kingdom. Sector: Healthcare / Biotechnology. Price 148p, market value 125 millionp.

## Valuation
- **P/E (trailing): n/a** (negative earnings). Diaceutics PLC reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **PEG: 0.34**. A PEG of 0.34 means the P/E is low relative to expected earnings growth: the market is not paying much for that growth.
- **Price / sales: 1.8×**. Each dollar of revenue is priced at 1.8×.
- **Price / book: 3.1×**. The shares trade at 3.1× book value; book value is a meaningful part of the valuation.
- **EV / EBITDA: 14.9×**. Enterprise value is 14.9× operating earnings before depreciation, the multiple that ignores how the company is financed.
- **Free-cash-flow yield: 1.7%** (5-yr avg -0.0%). Free cash flow equals 1.7% of the market value, above its five-year average of -0.0%, so the shares are cheaper on cash than they have usually been.

## Profitability
- **Gross margin: 77.2%**. Diaceutics PLC keeps 77.2% of revenue after the direct cost of what it sells, the kind of margin that comes with software, brands or pricing power.
- **Operating margin: -3.8%**. Operating margin is negative: the business loses money before interest and tax.
- **Net margin: 0.3%**. 0.3% of each dollar of sales reaches the bottom line.
- **Return on equity: 0.2%**. 0.2% on shareholders' equity is weak; the business earns little on the capital its owners have in it.
- **Return on invested capital: -7.8%**. Return on all capital, debt included, is -7.8%: close to or below the cost of capital, so growth may not create value.
- **Return on assets: -3.2%**. Each dollar of assets produces -3.2% of profit.

## Growth
- **Revenue growth (1 yr): 19.5%** (3-yr 25.4%/yr, 5-yr 24.8%/yr). Revenue grew 19.5% over the last year, against 24.8% a year compounded over five years: growth is slowing.
- **EPS growth (1 yr): 105.4%** (3-yr -49.2%/yr, 5-yr -20.2%/yr). Earnings per share rose 105.4%, faster than revenue, so margins expanded or the share count shrank.
- **Free-cash-flow growth (3 yr): 72.4%/yr**. Free cash flow has compounded at 72.4% a year over three years, keeping pace with earnings: the growth is real cash.

## Financial health
- **Debt to equity: 0.03**. Debt is 0.03 times equity: a conservative balance sheet.
- **Net debt / EBITDA: net cash**. Diaceutics PLC holds more cash than debt.
- **Interest coverage: -23.9×**. Operating profit covers interest only -23.9×: fragile.
- **Current ratio: 3.43** (quick 3.43). Current assets cover the next year's liabilities 3.43 times.
- **Altman Z-score: 10.35**. A Z-score of 10.35 places the company in the safe zone for bankruptcy risk.
- **Piotroski F-score: 6/9**. 6 of 9 checks pass: mixed.

## Dividends
- **Dividend: none**. Diaceutics PLC does not currently pay a dividend, but it returned -0.1% of its market value through buybacks over the last year.

## Price and momentum
- **Total return (1 yr): 4.2%** (YTD 16.4%, 3-mo 4.2%). The shares are up 4.2% over twelve months including dividends.
- **From 52-week high: -18.1%** (18.0% above the low). Trading 18% below its 52-week high.
- **200-day average: below**. The price sits below its 200-day moving average, the usual definition of a downtrend.
- **RSI (14-day): 59**. An RSI of 59 is neutral.
- **Beta (1 yr): 0.11** (volatility 32%). Beta of 0.11 against the FTSE All-Share: the shares move much less than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=DXRX.L · Page: https://foliofundamentals.com/stocks/dxrx.l

Not investment advice.